Prosecution Insights
Prosecution Insights
3 pending office actions • 3 art units • 3 examiners • 1 of 3 (33%) have an AI response strategy ready • 5 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| No statute on record | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JOHANSEN, PETER N. | 1 | 60.0% | +23.8% |
| MULDER, SCOTT EVAN | 1 | 30.8% | +63.9% |
| VIJAYARAGHAVAN, JAGAMYA NMN | 1 | 67.7% | +39.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18282767 | A BISPECIFIC ANTI-PD-L1/VEGF ANTIBODY AND USES THEREOF | JOHANSEN, PETER N. | 21d |
| 17996441 | A GENETICALLY MODIFIED CELL LINE PRODUCING A RECOMBINANT GLYCOPROTEIN HAVING A MANNOSE-TERMINATED N-GLYCAN | MULDER, SCOTT EVAN | 29d |
| 17572262 | TRANSCRIPTIONAL REGULATORY ELEMENT AND ITS USE IN ENHANCING THE EXPRESSION OF HETEROLOGOUS PROTEIN | VIJAYARAGHAVAN, JAGAMYA NMN | 54d |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| 1656 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18282767 | A BISPECIFIC ANTI-PD-L1/VEGF ANTIBODY AND USES THEREOF | JOHANSEN, PETER N. | 1644 | §103 | Non-Final OA | 21d | Pending | Sep 18, 2023 |
| 17996441 | A GENETICALLY MODIFIED CELL LINE PRODUCING A RECOMBINANT GLYCOPROTEIN HAVING A MANNOSE-TERMINATED N-GLYCAN | MULDER, SCOTT EVAN | 1656 | §103 | Final Rejection | 29d | AI Ready | Oct 18, 2022 |
| 17572262 | TRANSCRIPTIONAL REGULATORY ELEMENT AND ITS USE IN ENHANCING THE EXPRESSION OF HETEROLOGOUS PROTEIN | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | Other | Non-Final OA | 54d | Pending | Jan 10, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial